Explosive OTC stock: BSEM
BioStem is a manufacturer for wound care. Innovation new product and very succesful
Technical:
(+) Nice run from last year (product launch), volume increasing
(+) consolidation area lower volume
(-) wide range consolidation
Fundamental:
(+) New product launch in Q4/2023. Great revenue increase last quarter.
(+) Outlook Q4 > 100 Mio revenue --> except minimum 0,35 EPS next quarter.
(+) Market capitalization below revenue
(- / +) OTC stock, but want goes for nasdaq listing
Due to OTC listing, the stock could be a hidden gem but riskier.
Technical:
(+) Nice run from last year (product launch), volume increasing
(+) consolidation area lower volume
(-) wide range consolidation
Fundamental:
(+) New product launch in Q4/2023. Great revenue increase last quarter.
(+) Outlook Q4 > 100 Mio revenue --> except minimum 0,35 EPS next quarter.
(+) Market capitalization below revenue
(- / +) OTC stock, but want goes for nasdaq listing
Due to OTC listing, the stock could be a hidden gem but riskier.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。